[1]王 伟,足巴措,张 旭.补肺汤治疗慢性阻塞性肺疾病急性加重期疗效及对患者Th1/Th2漂移的影响[J].陕西中医,2023,(8):1078-1081.[doi:DOI:10.3969/j.issn.1000-7369.2023.08.018]
　WANG Wei,ZU Bacuo,ZHANG Xu.Effect of Bufei decoction on acute exacerbation of chronic obstructive pulmonary disease and its influence on Th1/Th2 drift[J].,2023,(8):1078-1081.[doi:DOI:10.3969/j.issn.1000-7369.2023.08.018]
点击复制

补肺汤治疗慢性阻塞性肺疾病急性加重期疗效及对患者Th1/Th2漂移的影响
分享到：

《陕西中医》[ISSN:1000-7369/CN:61-1281/TN]

卷:
期数:
2023年8期
页码:
1078-1081
栏目:
临床研究
出版日期:
2023-08-05

文章信息/Info

Title:
Effect of Bufei decoction on acute exacerbation of chronic obstructive pulmonary disease and its influence on Th1/Th2 drift
作者:
王 伟; 足巴措; 张 旭
(成都市第一人民医院 成都市中西医结合医院,四川 成都 610041)
Author(s):
WANG Wei; ZU Bacuo; ZHANG Xu
(Chengdu First People's Hospital,Chengdu 610041,China)
关键词:
慢性阻塞性肺疾病急性加重期;  肺气亏虚证;  补肺汤;  Th1/Th2漂移;  痰液生化指标;  血气指标
Keywords:
Acute exacerbation of chronic obstructive pulmonary disease;  Lung qi deficiency syndrome;  Bufei decoction;  Th1/Th2 drift;  Sputum biochemical indicators;  Blood gas indicators
分类号:
R 563
DOI:
DOI:10.3969/j.issn.1000-7369.2023.08.018
文献标志码:
A
摘要:
目的:探究补肺汤佐治慢性阻塞性肺疾病急性加重期(AECOPD)疗效及对血清辅助T细胞1/辅助T细胞2(Th1/Th2)漂移的影响。方法:选取224例AECOPD肺气亏虚证患者,采用单双球法随机分为对照组和观察组,每组112例,对照组给予常规治疗,观察组在对照组基础上给予补肺汤治疗。治疗2周后,比较两组患者临床疗效、中医症候积分、痰液生化指标[痰液黏蛋白(MUC5AC)、中性粒细胞弹性蛋白酶(NE)、白细胞弹性蛋白酶抑制因子(elafin)]、血气指标[二氧化碳分压(PaCO2)、氧分压(PaO2)、pH]、Th1/Th2漂移及白介素-17(IL-17)水平。结果:治疗后,观察组总有效率高于对照组(P<0.05)。治疗后两组患者中医证候积分、MUC5AC、NE、PaCO2、pH、IFN-γ、IL-4、IL-17水平较治疗前降低,观察组低于对照组(均P<0.05); 治疗后两组elafin、PaO2、IFN-γ/IL-4水平较治疗前升高,观察组高于对照组(均P<0.05)。结论:补肺汤治疗AECOPD肺气亏虚证患者疗效显著,可降低患者中医症候积分,改善患者痰液生化指标及血气指标,平衡免疫调节状态,缓解炎症反应。
Abstract:
Objective:To explore the efficacy of Bufei decoction on acute exacerbation of chronic obstructive pulmonary disease and its influence on T helper cell type 1/T helper cell type 2(Th1/Th2)drift.Methods:224 patients with AECOPD lung qi deficiency syndrome were selected and randomly divided into control group and observation group by single-double ball method,112 cases in each group.The control group was given conventional treatment,and the observation group was additionally given Bufei decoction on the basis of the control group.After two weeks of treatment,the clinical efficacy,scores of TCM syndromes,sputum biochemical indicators [sputum mucin5AC(MUC5AC),neutrophil elastase(NE),leukocyte elastase inhibitor(elafin)],blood gas indicators [partial pressure of carbon dioxide(PaCO2),partial pressure of oxygen(PaO2),pH] and levels of serum Th1/Th2 drift and interleukin-17(IL-17)were compared between the two groups.Results:After treatment,the total effective rate in observation group was higher than that in control group(P<0.05).The scores of TCM syndromes and levels of MUC5AC,NE,PaCO2,pH,IFN-γ,IL-4 and IL-17 in both groups were reduced compared with those before treatment,and above indicators in observation group were lower than those in control group(all P<0.05).The levels of elafin,PaO2 and IFN-γ/IL-4 in the two groups were reduced compared to before treatment,and above indicators in observation group were higher than those in control group(all P<0.05).Conclusion:Bufei decoction adjuvant therapy has a significant effect on patients with AECOPD lung qi deficiency syndrome,and it can reduce the TCM syndromes scores,improve the sputum and blood gas indicators,balance the immune regulation status,and relieve the inflammatory response of patients.

参考文献/References:

[1] 张 颖,陈 金,纪 靖,等.清肺化痰汤辅助治疗对AECOPD合并呼吸衰竭患者肺功能和血气指标及血清SP-1蛋白、FGF水平的影响[J].医学临床研究,2021,38(11):1745-1748.
[2] 叶双林,张文东,郭红兵.自拟痰热郁肺方联合加温加湿经鼻高流量氧疗仪治疗痰热郁肺型AECOPD疗效观察[J].四川中医,2021,39(9):87-90.
[3] 于得海,张 蕊.清肺化痰汤联合NIPPV治疗对痰热郁肺型AECOPD患者临床疗效、中医证候积分及炎性细胞因子的影响[J].辽宁中医杂志,2019,46(1):72-75.
[4] 宋采秋,马贤德,束 沛,等.都气丸合参苓白术散加减治疗慢性阻塞性肺疾病临床观察[J].辽宁中医药大学学报,2020,22(2):207-210.
[5] 赵 擘,刘建媛,赵 勇,等.化痰行瘀通腑汤保留灌肠联合特布他林治疗AECOPD痰热壅肺型患者疗效观察[J].世界中医药,2019,14(6):1455-1460.
[6] 慢性阻塞性肺疾病急性加重(AECOPD)诊治专家组.慢性阻塞性肺疾病急性加重(AECOPD)诊治中国专家共识(2017年更新版)[J].国际呼吸杂志,2017,37(14):1041-1057.
[7] 国家食品药品监督管理总局.中药新药临床研究指导原则[M].北京:中国医药科技出版社,2002:390-392.
[8] 阎 雪,路栋栋.罗氟司特联合布地奈德对慢性阻塞性肺疾病急性加重期患者呼吸力学指标及氧化应激反应的影响[J].陕西医学杂志,2022,51(1):73-76.
[9] 俞 洋,欧阳洋,杨晓龙,等.痰热清治疗对AECOPD患者症状、血气、肺功能指标及炎性因子水平的影响[J].现代生物医学进展,2020,20(5):897-900.
[10] 舒 攀,张 莉,侯云秋,等.逐瘀通脉消栓方预防慢性阻塞性肺疾病急性加重期机械通气患者下肢深静脉血栓临床研究[J].陕西中医,2021,42(9):1204-1207.
[11] 陈 坤,汤玲玲,王丽琼,等.补肺益气平喘汤联合正压通气治疗慢性阻塞性肺疾病急性加重期合并严重Ⅱ型呼吸衰竭临床研究[J].新中医,2021,53(8):55-58.
[12] 范 玲,王 鑫,朱晓静,等.紫菀化学成分及药理作用研究进展[J].吉林中医药,2019,39(2):269-273.
[13] 林 豪,王 阔,曾钦成,等.基于网络药理学和分子对接技术探讨五味子治疗慢性咳嗽的机制研究[J].北华大学学报:自然科学版,2022,23(4):466-470.
[14] 张一乐,史苗颜,孙 萌,等.补肾益肺方对慢性阻塞性肺疾病稳定期患者气道黏液高分泌及肺功能影响的临床研究[J].上海中医药杂志,2021,55(12):69-73.
[15] 王 杰,周向东,李 琪,等.系统性痰液分析技术在评估COPD病情进展中的意义[J].临床肺科杂志,2019,24(6):974-977.
[16] 李青林,姚汉玲.痰热清注射液对痰浊壅肺型AECOPD机械治疗患者肺功能与血气分析指标的影响[J].西部中医药,2021,34(1):98-102.
[17] 陈云坤,王 杰,刘 煌.清热化痰祛瘀方治疗AECOPD(痰热瘀肺证)患者的疗效观察[J].中国中医急症,2020,29(5):820-822,826.
[18] 于芳春,刘向国,方 芳,等.六味补气方对COPD模型大鼠Th1/Th2类细胞平衡调节作用的实验研究[J].陕西中医,2022,43(2):161-165.
[19] 余 刚,张飔雪.慢性阻塞性肺疾病急性加重期患者血清干扰素-γ、甲壳质酶蛋白-40水平及与预后、肺功能相关性分析[J].陕西医学杂志,2021,50(10):1223-1226.
[20] 刘秀玲,付雪梅,郑成彬.窄谱中波紫外线配合活血解毒方对血瘀型银屑病患者血液流变学及血清Th1/Th2细胞因子和IL-17表达的影响[J].中国美容医学,2022,31(1):102-107.
[21] 朱学懿,魏 颖,董竞成.黄芪治疗支气管哮喘的药理作用研究述评[J].中国中医基础医学杂志,2021,27(1):182-185.
[22] 陈思琦,李佳欣,吴鑫宇,等.熟地黄的药理学研究进展[J].化学工程师,2019,33(11):46-50.
[23] 刘倩倩,樊官伟.人参皂苷Rg3现代药理作用及作用机制的研究进展[J].中西医结合心脑血管病杂志,2022,20(13):2375-2381.
[24] 丁倩云,马双成,许风国,等.桑白皮的化学成分、药理及质量控制研究进展[J].药物分析杂志,2021,41(7):1114-1124.

相似文献/References:

[1]陈 荣,谢海道,符秀曼,等.资生丸颗粒联合穴位贴敷治疗慢性肺心病肺气亏虚证疗效研究[J].陕西中医,2022,(12):1793.[doi:DOI:10.3969/j.issn.1000-7369.2022.12.036]
　CHEN Rong,XIE Haidao,FU Xiuman,et al.Effect study on Zisheng Wan combined with acupoint application in treatment of chronic pulmonary heart disease of Feiqi Kuixu type[J].,2022,(8):1793.[doi:DOI:10.3969/j.issn.1000-7369.2022.12.036]
[2]向 杰,杨 峰,李 强,等.小柴胡汤加味治疗慢性阻塞性肺疾病急性加重期疗效及对患者细胞免疫状态的影响[J].陕西中医,2023,(5):591.[doi:DOI:10.3969/j.issn.1000-7369.2023.05.011]
　XIANG Jie,YANG Feng,LI Qiang,et al.Efficacy of modified Xiaochaihu decoction in the treatment of chronic obstructive pulmonary disease and its influence on cellular immune status[J].,2023,(8):591.[doi:DOI:10.3969/j.issn.1000-7369.2023.05.011]

备注/Memo

备注/Memo:
基金项目:四川省科技计划项目(2021YFS0272)
更新日期/Last Update: 2023-08-10